NAS:NYMX (Bahamas) Also trade in: Germany

Nymox Pharmaceutical Corp

$ 1.73 -0.17 (-8.95%)
Volume: 86,195 Avg Vol (1m): 82,316
Market Cap $: 117.51 Mil Enterprise Value $: 106.22 Mil
P/E (TTM): 0.00 P/B: 11.53
Earnings Power Value -13.58
Net Current Asset Value 0.15
Tangible Book 0.15
Projected FCF -0.69
Median P/S Value 0.43
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
95.08% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NYMX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.19, Med: 10000, Max: 10000
Current: 10000
0.19
10000
Equity-to-Asset 0.86
Equity-to-Asset ranked lower than
97.77% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NYMX: 0.86
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -7.82, Med: 0.26, Max: 1
Current: 0.86
-7.82
1
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 24.53
DISTRESS
GREY
SAFE
Beneish M-Score -3.68
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 16.71%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -6155.93
Operating Margin ranked lower than
87.37% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NYMX: -6155.93
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -6155.93, Med: -790.39, Max: -145.43
Current: -6155.93
-6155.93
-145.43
Net Margin % -6101.69
Net Margin ranked lower than
88.26% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NYMX: -6101.69
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -6101.69, Med: -796.87, Max: -146.14
Current: -6101.69
-6101.69
-146.14
ROE % -229.51
ROE ranked lower than
100.00% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NYMX: -229.51
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -368.42, Med: -368.42, Max: -229.51
Current: -229.51
-368.42
-229.51
ROA % -175.47
ROA ranked lower than
99.26% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NYMX: -175.47
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -1676.25, Med: -372.78, Max: -89.58
Current: -175.47
-1676.25
-89.58
ROC (Joel Greenblatt) % -70331.17
ROC (Joel Greenblatt) ranked lower than
99.81% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NYMX: -70331.17
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -891800, Med: -47102.21, Max: -26973.68
Current: -70331.17
-891800
-26973.68
3-Year Total Revenue Growth Rate -52.30
3-Year Revenue Growth Rate ranked lower than
86.48% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
NYMX: -59.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -63.8, Med: 4.6, Max: 91.3
Current: -59.3
-63.8
91.3
3-Year Total EBITDA Growth Rate 15.90
3-Year EBITDA Growth Rate ranked lower than
77.06% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
NYMX: 28.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -27.8, Med: 0.3, Max: 28.4
Current: 28.4
-27.8
28.4
3-Year EPS w/o NRI Growth Rate 27.90
3-Year EPS w/o NRI Growth Rate ranked lower than
80.34% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
NYMX: 27.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -27.8, Med: 0, Max: 27.9
Current: 27.9
-27.8
27.9

» NYMX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-13)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NYMX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2835
Compare LSE:TILS TPE:1733 NAS:BLCM NAS:SBPH AMEX:AGE NAS:SURF NAS:TOCA NAS:DYAI XKRX:046210 TSE:4576 ROCO:6497 XKRX:002630 NAS:AQST NAS:EQ OTCPK:BIXT NAS:SELB NAS:INMB XTAE:CBI NAS:NK NAS:MDWD
Traded in other countries NYM.Germany
Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company. The firm and its subsidiaries specialize in research and development of drugs and diagnostic products for aging population. Its product portfolio consists of Nic alert and Tobac alert. The firm has Research and development of products for the aging population reportable segment. It operates mainly in Canada, the United States and Europe and other countries. The company generates majority of its sales from the United States.

Ratios

Current vs industry vs history
PB Ratio 11.53
PB Ratio ranked lower than
100.00% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NYMX: 11.53
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 9.87, Med: 41.11, Max: 93.13
Current: 11.53
9.87
93.13
PS Ratio 865.00
PS Ratio ranked lower than
93.53% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NYMX: 865
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.98, Med: 214.24, Max: 1175
Current: 865
3.98
1175
EV-to-EBIT -9.81
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NYMX: -9.81
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -161.8, Med: -22.5, Max: -2.6
Current: -9.81
-161.8
-2.6
EV-to-EBITDA -10.15
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NYMX: -10.15
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -164.2, Med: -22.95, Max: -2.6
Current: -10.15
-164.2
-2.6
EV-to-Revenue 600.09
EV-to-Revenue ranked lower than
92.48% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NYMX: 600.09
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 4.2, Med: 212.3, Max: 1343.5
Current: 600.09
4.2
1343.5
Current Ratio 8.04
Current Ratio ranked lower than
94.60% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NYMX: 8.04
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.12, Med: 0.68, Max: 42.02
Current: 8.04
0.12
42.02
Quick Ratio 8.01
Quick Ratio ranked lower than
93.48% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NYMX: 8.01
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.09, Med: 0.62, Max: 42.02
Current: 8.01
0.09
42.02
Days Inventory 116.66
Days Inventory ranked higher than
84.41% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
NYMX: 116.66
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 22.05, Med: 45.7, Max: 143.72
Current: 116.66
22.05
143.72
Days Sales Outstanding 20.62
Days Sales Outstanding ranked higher than
85.18% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
NYMX: 20.62
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.13, Med: 4.78, Max: 128.73
Current: 20.62
0.13
128.73
Days Payable 2.00
Days Payable ranked lower than
91.04% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
NYMX: 2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 2, Med: 2313.07, Max: 4940.97
Current: 2
2
4940.97

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.40
3-Year Share Buyback Rate ranked lower than
56.48% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
NYMX: -12.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -16.3, Med: -4.6, Max: -2.1
Current: -12.4
-16.3
-2.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 11.53
Price-to-Tangible-Book ranked lower than
100.00% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NYMX: 11.53
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 11.53, Med: 29.61, Max: 350
Current: 11.53
11.53
350
Price-to-Median-PS-Value 4.02
Price-to-Median-PS-Value ranked lower than
85.84% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
NYMX: 4.02
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.02, Med: 1.09, Max: 5.12
Current: 4.02
0.02
5.12
Earnings Yield (Joel Greenblatt) % -10.21
Earnings Yield (Greenblatt) ranked higher than
51.71% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NYMX: -10.21
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -38.5, Med: -4.45, Max: -0.6
Current: -10.21
-38.5
-0.6

More Statistics

Revenue (TTM) (Mil) $ 0.18
EPS (TTM) $ -0.18
Beta 2.45
Volatility % 86.82
52-Week Range $ 1.25 - 3.9
Shares Outstanding (Mil) 67.93

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y